LOTEPREDNOL ETABONATE AND TOBRAMYCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Loteprednol Etabonate And Tobramycin, and when can generic versions of Loteprednol Etabonate And Tobramycin launch?
Loteprednol Etabonate And Tobramycin is a drug marketed by Alembic and is included in one NDA.
The generic ingredient in LOTEPREDNOL ETABONATE AND TOBRAMYCIN is loteprednol etabonate; tobramycin. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the loteprednol etabonate; tobramycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Loteprednol Etabonate And Tobramycin
A generic version of LOTEPREDNOL ETABONATE AND TOBRAMYCIN was approved as loteprednol etabonate; tobramycin by ALEMBIC on December 10th, 2025.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LOTEPREDNOL ETABONATE AND TOBRAMYCIN?
- What are the global sales for LOTEPREDNOL ETABONATE AND TOBRAMYCIN?
- What is Average Wholesale Price for LOTEPREDNOL ETABONATE AND TOBRAMYCIN?
Summary for LOTEPREDNOL ETABONATE AND TOBRAMYCIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Clinical Trials: | 7 |
| What excipients (inactive ingredients) are in LOTEPREDNOL ETABONATE AND TOBRAMYCIN? | LOTEPREDNOL ETABONATE AND TOBRAMYCIN excipients list |
| DailyMed Link: | LOTEPREDNOL ETABONATE AND TOBRAMYCIN at DailyMed |
Recent Clinical Trials for LOTEPREDNOL ETABONATE AND TOBRAMYCIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Second Affiliated Hospital of Nanchang University | Phase 1 |
| Zhongshan Ophthalmic Center, Sun Yat-sen University | Phase 4 |
| Bausch & Lomb Incorporated | Phase 3 |
See all LOTEPREDNOL ETABONATE AND TOBRAMYCIN clinical trials
Pharmacology for LOTEPREDNOL ETABONATE AND TOBRAMYCIN
| Drug Class | Aminoglycoside Antibacterial Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for LOTEPREDNOL ETABONATE AND TOBRAMYCIN
LOTEPREDNOL ETABONATE AND TOBRAMYCIN is protected by zero US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alembic | LOTEPREDNOL ETABONATE AND TOBRAMYCIN | loteprednol etabonate; tobramycin | SUSPENSION/DROPS;OPHTHALMIC | 217597-001 | Dec 10, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
